Company profile: CytoDyn
1.1 - Company Overview
Company description
- Provider of biotechnology therapies developing Leronlimab, a CCR5-targeting humanized monoclonal antibody for HIV to prevent viral entry into T-cells; exploring uses in NASH to address liver health, fibrosis and cirrhosis; oncology to inhibit tumor growth and metastasis; COVID-19 to modulate immune response and potentially reduce inflammation; and pre-clinical glioblastoma studies.
Products and services
- Leronlimab for Cancer: An investigational CCR5-blockade product that aims to inhibit tumor growth and metastasis by limiting chemokine-driven cancer cell migration in oncology applications
- Leronlimab for COVID-19: An investigational product modulating immune response via CCR5 to potentially reduce inflammation and improve SARS‑CoV‑2 disease management in cytokine-mediated complications
- Leronlimab for HIV: A humanized, CCR5-targeting monoclonal antibody that prevents HIV from entering healthy T-cells, preserving immune function and supporting treatment of immune deficiency virus infection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CytoDyn
Ventyx Biosciences
HQ: United States
Website
- Description: Provider of oral therapies for autoimmune, inflammatory and neurodegenerative disorders: VTX3232, a CNS-penetrant NLRP3 inhibitor for Parkinson’s, obesity, Alzheimer’s and multiple sclerosis; VTX2735, an NLRP3 inhibitor for systemic inflammation, initially cardiovascular; VTX002, an S1P1R modulator for ulcerative colitis; and VTX958, a TYK2 inhibitor for Crohn’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ventyx Biosciences company profile →
Kanyos
HQ: United States
Website
- Description: Provider of antigen-specific immune tolerance technology focused on two autoimmune indications: type 1 diabetes and celiac disease. Technology originated at EPFL in Switzerland and is being developed in collaboration with sister company Anokion.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kanyos company profile →
Genome Diagnostics
HQ: The Netherlands
Website
- Description: Provider of in vitro diagnostic tests and services, molecular diagnostic kits, analysis software, and education for transplantation and companion diagnostics. Delivers sequencing-based, high-resolution HLA typing for Sanger and NGS, NGSgo workflows, Oxford Nanopore solutions (NGS-Pronto, NGS-Turbo), NGSengine-Turbo software, and chimerism monitoring assays and software (NGStrack, TRKengine).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genome Diagnostics company profile →
Greer Laboratories
HQ: United States
Website
- Description: Provider of subcutaneous immunotherapy and allergenic extracts for allergy diagnosis and treatment, including non-standardized extracts; short ragweed pollen and short/giant ragweed pollen mix extracts; standardized cat hair extracts for asthma, rhinitis, and conjunctivitis; and standardized grass pollen extracts for skin test diagnosis and immunotherapy to reduce allergic symptoms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Greer Laboratories company profile →
Corbus Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting inflammatory and fibrotic diseases, with programs in oncology and obesity. Pipeline includes CRB-701, a next-generation Nectin-4-targeting ADC in trials for advanced solid tumors; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a peripherally restricted CB1 inverse agonist for obesity with IND planned.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corbus Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CytoDyn
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CytoDyn
2.2 - Growth funds investing in similar companies to CytoDyn
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CytoDyn
4.2 - Public trading comparable groups for CytoDyn
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →